Real ‐world incidence of efficacy and safety outcomes in patients on direct oral anticoagulants with left ventricular systolic dysfunction at a tertiary referral center

ConclusionsOur findings are largely compatible with the results of LVSD or HF subgroups in RE‐LY, ROCKET‐AF, and ARISTOTLE trials and add to increasing confidence that DOACs can be safely used for stroke and systemic embolism prevention in patients with LVSD.

Source: Clinical Cardiology - November 1, 2017 Category: Cardiology Authors: Andrew S. Tseng, J. William Schleifer, Win ‐Kuang Shen, Robert McBane, Sunil Mankad, Heidi Esser, Darko Vucicevic, Fadi E. Shamoun Tags: CLINICAL INVESTIGATIONS Source Type: research